2219.HK
Chaoju Eye Care Holdings Limited [2219.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2219.HK Stock Summary
Top 10 Correlated ETFs
2219.HK
Top 10 Correlated Stocks
2219.HK
In the News
2219.HK Financial details
Company Rating
Buy
Market Cap
2.63B
Income
234.77M
Revenue
1.15B
Book val./share
3.21
Cash/share
2.31
Dividend
0.17
Dividend %
4.19%
Employees
1.43K
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
14.3
Forward P/E
-
PEG
4.68
P/S
2.82
P/B
1.18
P/C
1.56
P/FCF
18.85
Quick Ratio
6.86
Current Ratio
7.41
Debt / Equity
0.08
LT Debt / Equity
0.06
-
-
EPS (TTM)
0.34
EPS next Y
-
EPS next Q
-
EPS this Y
3.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
36.83%
Revenue last 5Y
9.37%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-6.95%
SMA50
1.35%
SMA100
-10.29%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
9%
ROC
0.1%
Gross Margin
44%
Oper. Margin
26%
Profit Margin
19%
Payout
33%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.5-6.3
52W High
-39.83%
52W Low
+20.33%
RSI
36.75
Rel Volume
0.35
Avg Volume
1.28M
Volume
454.5K
Perf Week
-6.23%
Perf Month
-8.84%
Perf Quarter
-5.5%
Perf Half Y
-8.14%
-
-
-
-
Beta
0.361
-
-
Volatility
0.07%, 0.15%
Prev Close
-1.63%
Price
3.61
Change
-1.9%
2219.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.92 | 1.04 | 1.16 | 1.6 | 1.4 | |
| Net income per share | 0.06 | 0.11 | 0.18 | 0.26 | 0.27 | |
| Operating cash flow per share | 0.13 | 0.23 | 0.36 | 0.4 | 0.39 | |
| Free cash flow per share | -0.01 | 0.17 | 0.29 | 0.3 | 0.21 | |
| Cash per share | 0.23 | 0.35 | 0.61 | 2.85 | 2.38 | |
| Book value per share | 0.6 | 0.76 | 1.07 | 3.37 | 3.22 | |
| Tangible book value per share | 0.52 | 0.68 | 0.99 | 3.28 | 2.96 | |
| Share holders equity per share | 0.6 | 0.76 | 1.07 | 3.37 | 3.22 | |
| Interest debt per share | 0.56 | 0.39 | 0.23 | 0.3 | 0.29 | |
| Market cap | 8.51B | 8.66B | 8.16B | 3.26B | 2.64B | |
| Enterprise value | 8.71B | 8.66B | 7.89B | 2.18B | 1.89B | |
| P/E ratio | 219.75 | 114.41 | 65.71 | 20.14 | 14.06 | |
| Price to sales ratio | 13.45 | 12.11 | 10.27 | 3.26 | 2.67 | |
| POCF ratio | 94.06 | 55.52 | 32.79 | 13.06 | 9.65 | |
| PFCF ratio | -1.22K | 73.82 | 41.58 | 17.22 | 17.8 | |
| P/B Ratio | 20.71 | 16.59 | 11.06 | 1.55 | 1.16 | |
| PTB ratio | 20.71 | 16.59 | 11.06 | 1.55 | 1.16 | |
| EV to sales | 13.77 | 12.12 | 9.93 | 2.18 | 1.91 | |
| Enterprise value over EBITDA | 58.5 | 42.03 | 30.36 | 6.85 | 8.06 | |
| EV to operating cash flow | 96.33 | 55.56 | 31.7 | 8.74 | 6.91 | |
| EV to free cash flow | -1.25K | 73.87 | 40.2 | 11.52 | 12.75 | |
| Earnings yield | 0 | 0.01 | 0.02 | 0.05 | 0.07 | |
| Free cash flow yield | 0 | 0.01 | 0.02 | 0.06 | 0.06 | |
| Debt to equity | 0.88 | 0.47 | 0.19 | 0.08 | 0.09 | |
| Debt to assets | 0.34 | 0.24 | 0.13 | 0.07 | 0.07 | |
| Net debt to EBITDA | 1.38 | 0.03 | -1.04 | -3.39 | -3.19 | |
| Current ratio | 1.17 | 1.53 | 2.73 | 8.63 | 7.41 | |
| Interest coverage | 3.3 | 5.68 | 14.32 | 22.26 | 21.48 | |
| Income quality | 1.91 | 1.69 | 1.58 | 1.18 | 1.14 | |
| Dividend Yield | 0 | 0 | 0 | 0.03 | 0.02 | |
| Payout ratio | 0 | 0 | 0.27 | 0.7 | 0.33 | |
| Sales general and administrative to revenue | 0.06 | 0.05 | 0.05 | 0.18 | 0.16 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.08 | 0.09 | 0.08 | 0.03 | 0.08 | |
| Capex to operating cash flow | -1.08 | -0.25 | -0.21 | -0.24 | -0.46 | |
| Capex to revenue | -0.15 | -0.05 | -0.07 | -0.06 | -0.13 | |
| Capex to depreciation | -1.36 | -0.51 | -0.68 | -0.72 | -1.26 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0.01 | 0 | |
| Graham number | 0.87 | 1.37 | 2.09 | 4.43 | 4.39 | |
| ROIC | 0.05 | 0.11 | 0.14 | 0.07 | 0.07 | |
| Return on tangible assets | 0.04 | 0.08 | 0.12 | 0.07 | 0.07 | |
| Graham Net | -0.64 | -0.19 | 0.23 | 2.33 | 1.87 | |
| Working capital | 70.29M | 141.99M | 342.85M | 1.69B | 1.57B | |
| Tangible asset value | 358.99M | 466.93M | 678.84M | 2.05B | 2.09B | |
| Net current asset value | -145.31M | -36.05M | 216.03M | 1.54B | 1.39B | |
| Invested capital | 0.88 | 0.47 | 0.19 | 0.08 | 0.09 | |
| Average receivables | 0 | 36.13M | 67.29M | 58.25M | 50.41M | |
| Average payables | 0 | 56.6M | 44.91M | 38.05M | 40.41M | |
| Average inventory | 0 | 41.31M | 37.03M | 36.45M | 43.66M | |
| Days sales outstanding | 0 | 36.9 | 28.64 | 19.81 | 17.2 | |
| Days payables outstanding | 58.99 | 42.25 | 32.24 | 24.46 | 28.94 | |
| Days of inventory on hand | 43.83 | 30.14 | 31.18 | 23.2 | 34.45 | |
| Receivables turnover | 0 | 9.89 | 12.74 | 18.42 | 21.23 | |
| Payables turnover | 6.19 | 8.64 | 11.32 | 14.92 | 12.61 | |
| Inventory turnover | 8.33 | 12.11 | 11.71 | 15.73 | 10.6 | |
| ROE | 0.09 | 0.15 | 0.17 | 0.08 | 0.08 | |
| Capex per share | -0.14 | -0.06 | -0.08 | -0.1 | -0.18 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.38 | 0.32 | 0.32 | 0.48 | 0.48 | |
| Net income per share | 0.07 | 0.06 | 0.06 | 0.11 | 0.11 | |
| Operating cash flow per share | 0.11 | 0.08 | 0.08 | 0.14 | 0.14 | |
| Free cash flow per share | 0.05 | 0.06 | 0.06 | 0.1 | 0.1 | |
| Cash per share | 2.51 | 1.86 | 2.38 | 1.27 | 2.31 | |
| Book value per share | 3.08 | 3.22 | 3.22 | 3.21 | 3.21 | |
| Tangible book value per share | 2.99 | 2.97 | 2.97 | 2.91 | 2.91 | |
| Share holders equity per share | 3.08 | 3.22 | 3.22 | 3.21 | 3.21 | |
| Interest debt per share | 0.25 | 0 | 0.29 | 0 | 0.28 | |
| Market cap | 2.87B | 2.37B | 2.63B | 3.32B | 3.08B | |
| Enterprise value | 1.63B | 1.43B | 1.89B | 2.9B | 2.86B | |
| P/E ratio | 13.85 | 14.09 | 15.65 | 11.01 | 10.23 | |
| Price to sales ratio | 10.77 | 10.37 | 11.52 | 9.58 | 8.9 | |
| POCF ratio | 36.61 | 40.64 | 45.15 | 34.06 | 31.64 | |
| PFCF ratio | 80.05 | 58.8 | 65.33 | 44.07 | 40.94 | |
| P/B Ratio | 1.32 | 1.04 | 1.16 | 1.44 | 1.34 | |
| PTB ratio | 1.32 | 1.04 | 1.16 | 1.44 | 1.34 | |
| EV to sales | 6.13 | 6.24 | 8.25 | 8.38 | 8.26 | |
| Enterprise value over EBITDA | 21.81 | 24.15 | 31.92 | 29.8 | 29.36 | |
| EV to operating cash flow | 20.84 | 24.45 | 32.32 | 29.81 | 29.36 | |
| EV to free cash flow | 45.56 | 35.38 | 46.76 | 38.57 | 37.99 | |
| Earnings yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Free cash flow yield | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Debt to equity | 0.08 | 0 | 0.09 | 0 | 0.08 | |
| Debt to assets | 0.07 | 0 | 0.07 | 0 | 0.07 | |
| Net debt to EBITDA | -16.52 | -15.99 | -12.67 | -4.25 | -2.28 | |
| Current ratio | 7.8 | 7.41 | 7.41 | 5.4 | 5.4 | |
| Interest coverage | 0 | 0 | 6.28 | 0 | 12.38 | |
| Income quality | 1.51 | 1.39 | 1.39 | 1.29 | 1.29 | |
| Dividend Yield | 0.01 | 0 | 0 | 0.02 | 0.02 | |
| Payout ratio | 0.61 | 0 | 0.13 | 0.73 | 0.73 | |
| Sales general and administrative to revenue | 0.17 | 0.15 | 0.15 | 0.16 | 0.16 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.03 | 0.08 | 0.08 | 0.08 | 0.08 | |
| Capex to operating cash flow | -0.54 | -0.31 | -0.31 | -0.23 | -0.23 | |
| Capex to revenue | -0.16 | -0.08 | -0.08 | -0.06 | -0.06 | |
| Capex to depreciation | -1.79 | -0.71 | -0.71 | -0.75 | -0.75 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.25 | 2.08 | 2.08 | 2.75 | 2.75 | |
| ROIC | 0.02 | 0.01 | 0.01 | 0.03 | 0.02 | |
| Return on tangible assets | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Graham Net | 2.04 | 1.35 | 1.87 | 0.68 | 1.71 | |
| Working capital | 1.68B | 1.57B | 1.57B | 1.51B | 1.51B | |
| Tangible asset value | 2.12B | 2.09B | 2.09B | 2.09B | 2.09B | |
| Net current asset value | 1.52B | 1.39B | 1.39B | 1.34B | 1.34B | |
| Invested capital | 0.08 | 0 | 0.09 | 0 | 0.08 | |
| Average receivables | 0 | 55.93M | 46.65M | 56.24M | 65.84M | |
| Average payables | 0 | 51.75M | 44.03M | 53.24M | 62.46M | |
| Average inventory | 0 | 49.51M | 52.42M | 56.21M | 60M | |
| Days sales outstanding | 22.04 | 18.36 | 18.36 | 17.11 | 17.11 | |
| Days payables outstanding | 37.12 | 29.69 | 29.69 | 30.41 | 30.41 | |
| Days of inventory on hand | 29.09 | 35.34 | 35.34 | 29.21 | 29.21 | |
| Receivables turnover | 4.08 | 4.9 | 4.9 | 5.26 | 5.26 | |
| Payables turnover | 2.42 | 3.03 | 3.03 | 2.96 | 2.96 | |
| Inventory turnover | 3.09 | 2.55 | 2.55 | 3.08 | 3.08 | |
| ROE | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Capex per share | -0.06 | -0.03 | -0.03 | -0.03 | -0.03 |
2219.HK Frequently Asked Questions
What is Chaoju Eye Care Holdings Limited stock symbol ?
Chaoju Eye Care Holdings Limited is a CN stock and trading under the symbol 2219.HK
What is Chaoju Eye Care Holdings Limited stock quote today ?
Chaoju Eye Care Holdings Limited stock price is $3.61 today.
Is Chaoju Eye Care Holdings Limited stock public?
Yes, Chaoju Eye Care Holdings Limited is a publicly traded company.
Company Profile
- Volume Average 1.28M
- Market Capitalization 2.63B
- Employee 1.43K
- CEO Mr. Bozhou Zhang
- Headquarters Beijing,CN
- IPO Date 2021-07-07
-
Website
https://www.chaojueye.com 
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, and myopia control, as well as optical products and services. The company also provides basic ophthalmic services, including cataract, glaucoma, ocular fundus diseases, ocular muscle diseases, refraction errors, pediatric ophthalmology, ocular surface diseases, lacrimal diseases, orbital diseases, oculoplastic, and ocular trauma. As of December 31, 2021, it operated a network of 17 ophthalmic hospitals, 24 optical centers, and 2 clinics in Zhejiang, Jiangsu, Shanxi, and Hebei provinces, as well as in Inner Mongolia. The company was founded in 1988 and is headquartered in Beijing, China.
